SCHEDULE: Daphne Zohar Reports 9.1% Stake in Seaport Therapeutics

Daphne Zohar has disclosed a beneficial ownership of 9.1% in Seaport Therapeutics, Inc., holding over 5.2 million shares.

Summary

• Daphne Zohar has filed a Schedule 13G, indicating a significant ownership stake in Seaport Therapeutics, Inc.
• As of June 30, 2026, the Reporting Person beneficially owns 5,225,497 shares of common stock.
• This represents 9.1% of the outstanding common stock, which totaled 53,530,550 shares as of the same date.
• The reported shares include 1,194,001 shares held directly and 4,031,496 shares subject to stock options exercisable within 60 days.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily indicating a significant ownership stake by an individual, which can be interpreted as confidence in the company's future, but without new strategic or financial performance data.

Positives

• Significant individual ownership stake (9.1%) by Daphne Zohar, suggesting potential confidence in the company's prospects.
• The ownership includes both directly held shares and exercisable stock options, indicating a vested interest in the company's performance.

Negatives

• The filing does not provide any new financial performance data, strategic updates, or forward-looking guidance.
• It is a routine disclosure of ownership and does not offer insights into the company's operational health or future plans.

Risks

• Concentration of ownership in a single individual could lead to potential influence over corporate decisions, the impact of which is not detailed.
• The filing does not provide information on the source or strategy behind this significant stake, leaving its implications open to interpretation.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for significant institutional or individual investors acquiring a substantial stake in a public company. This filing indicates Daphne Zohar's substantial interest in Seaport Therapeutics, but without further context from the company, it's difficult to ascertain the strategic implications beyond a large ownership position.

Stakeholder Impact

• Shareholders: The significant stake held by Daphne Zohar may influence corporate governance and strategic decisions, the impact of which is yet to be determined.
• Management: May face increased scrutiny or influence from a major shareholder with a substantial ownership percentage.

Key Dates

Keywords

Seaport Therapeutics, Schedule 13G, Beneficial Ownership, Daphne Zohar, Common Stock, Stock Options